US · Healthcare · Medical Devices
EPS came in at -0.14 against a street estimate of -0.28 — a beat of 50.0%.
Analysts rate Glaukos Corp a strong buy (13 buy, 1 hold, 0 sell out of 14) with an average price target of $199.31.
CONFIDENT Glaukos delivered record Q2 revenue of $185.6M (+50% YoY), raised full-year guidance to $680–700M. iDose TR and Epioxa driving growth; executing on commercial launches while advancing pipeline. Q2 2026 U.S. represents majority revenue; international growth decelerating due to FX headwinds and competitive pressure, but MIGS expansion continues globally. Analysts probed iDose LCD risk, Epioxa pricing/340B impact, and prior-auth backlog timing. Management emphasized no LCD pull-forward, conservative gross-to-net assumptions, and strong early demand backlog with Q3 J-code transition uncertainty. 2026-07-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 16.17% |
| HHG PLC | 9.07% |
| Jupiter Topco LLC | 8.24% |
| Vanguard Portfolio Management, LLC | 5.63% |
| PRIMECAP Management Company | 5.16% |
| Vanguard Capital Management, LLC | 4.33% |
| State Street Corp | 3.93% |
| Millennium Management LLC | 2.68% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q3 2026 GLAUKOS CORPORATION (GKOS) - 8-K FILING SUMMARY HEADLINE NUMBERS • Filing Date: August 3, 2026 • Company: Glaukos Corporation, Delaware incorporatio | 2026-08-03 |
| Quarterly report · Q2 2026 GLAUKOS CORPORATION - 10-Q SUMMARY (Q2 2026) HEADLINE NUMBERS • Net Sales (6 months ended June 30, 2026): $336.2 million vs. $230.8 million in prior | 2026-07-29 |
| Results announced · Q3 2026 GLAUKOS CORPORATION (GKOS) – Q2 2026 SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Q2 2026 revenue: $185.6 million, up 50% year-over-year (49% con | 2026-07-29 |
| Shareholder vote results · Q2 2026 GLAUKOS CORPORATION - 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held May 28, 2026 • Total votes cast across proposals: approximately | 2026-06-03 |
| Reg FD disclosure · Q2 2026 GLAUKOS CORPORATION (GKOS) - 8-K SUMMARY HEADLINE NUMBERS • Filing Date: May 4, 2026 • Company: Glaukos Corporation, Delaware incorporated • Stock T | 2026-05-04 |
| Quarterly report · Q1 2026 GLAUKOS CORPORATION - 10-Q SUMMARY Q1 2026 (Quarter Ended March 31, 2026) --- HEADLINE NUMBERS • Net sales: $150.6 million (Q1 2026) vs. $106.7 mil | 2026-04-30 |
| Proxy statement · Q2 2026 GLAUKOS CORPORATION (GKOS) – 2026 PROXY SUMMARY --- WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect two Class II directors (Denice M. Torres an | 2026-04-16 |
| Annual report FY2025 GLAUKOS CORPORATION – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Market capitalization: $5,913 million (as of June 30, 2025) • Shares outs | 2026-02-23 |
Readable in the app.
| Announcement | Date |
|---|---|
| Raised 2026 net sales guidance to $680-700 million from $620-635 million Glaukos Corporation reported exceptional Q2 2026 results that exceeded expectations. Net sales reached a record $185.6 million, representing 50% year-over-year growth. Glaucoma-specific sale | 2026-07-29 |
| Raises 2026 net sales guidance to $620-635 million from $600-620 million Glaukos, an eye disease treatment company, reported strong Q1 2026 results that exceeded expectations. Key highlights: Record quarterly sales of $150.6 million, up 41% year-over-year (39% ad | 2026-04-29 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Glaukos Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-19.